IMR Press / CEOG / Volume 42 / Issue 1 / DOI: 10.12891/ceog1892.2015

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Effect of hypertonic sodium chloride hydroxyethyl starch 40 on ET, TXB2, 6-keto-PGF1α, and ANP of preeclampsia in caesarean section
Show Less
1 Department of Anesthesia, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou
2 The First Affiliated Hospital of Henan Chinese Medical College, Zhengzhou (China)
Clin. Exp. Obstet. Gynecol. 2015, 42(1), 36–39;
Published: 10 February 2015
Objective: Preeclampsia is a unique disease of pregnancy. Delivery via caesarean section is the most important way of terminating thepregnancy and treating preeclampsia. Perioperative fluid therapy is performed to maintain the circulatory volume and reduce tissue edema.This study evaluated the effects of hypertonic sodium chloride hydroxyethyl starch 40 (HSH40) as perioperative fluid therapy forpreeclampsia patients. Materials and Methods: Forty preeclamptic women were randomly divided into two groups: the Ringer’s solutiongroup and the HSH40 group. Their ECG, HR, MAP, and SPO2 were monitored. Their MVP and HR were recorded at five, eight, and tenminutes after anesthesia induction and at the end of the caesarean section. The corresponding volume of infusion, blood loss, and urineoutput during the operation were also recorded. Venous samples were collected before HSH40 infusion and 30 min after infusion to measurethe plasma concentrations of ET, TXB2, 6-keto-PGF1α, and ANP via a radioimmunoassay. Results: HSH40 infusion significantly decreasedthe plasma ET levels (p < 0.01), significantly changed the plasma ANP and TXB2 levels (p < 0.05), and significantly increasedthe plasma 6-keto-PGF1α levels (p < 0.01) in the experimental group compared with those before infusion. The plasma levels of ET, ANP, TXB2, and 6-keto-PGF1α did not significantly change in the control group. Compared with T1, MAP decreased significantly at T2, T3, T4, and T5 within groups (p < 0.05) and between the two groups. MAP significantly changed at T2, T3, T4, and T5 (p < 0.05). HR didnot significant change at T1, T2, T3, T4, and T5 within or between groups. Volume of infusion and urine volume significantly differedbetween groups (p < 0.05). Conclusion: Low-dose HSH40 lowers the plasma levels of vasoconstrictor substances (ET and TXB2) andincreases the levels of vasodilator substances (6-keto-PGF1α and ANP) during preeclampsia. It effectively maintains and stabilizes thecirculating blood volume, increasing renal blood flow, which improves renal function and increases urine output.
Hypertonic sodium chloride hydroxyethyl starch
Atrial natriuretic peptide
Back to top